Liquid biopsy is reaching a critical inflection point in precision oncology, yet its full potential remains largely untapped.
This panel explores how decentralized models, AI-powered analytics, and ecosystem-level collaborations are driving broader liquid biopsy adoption. Experts will trace the evolution of MSK-ACCESS® powered with SOPHiA DDM™ from an innovative in-house test to a globally scalable solution and examine how the shared vision between SOPHiA GENETICS and MSK has the potential to transform the future of precision oncology.
Monday, May 4, 15:30 - 16:15, room Delhi
| Name | Position | Institution |
|---|---|---|
| Philippe Menu, MD, PhD | EVP, Chief Medical Officer & Chief Product Officer | SOPHiA GENETICS |
| Name | Position | Institution |
|---|---|---|
| Thomas di Maio | EU/Canada Diagnostic Lead | AstraZeneca |
| Elena Guerini Rocco | Director of the Oncology Genetics Unit | IEO - Istituto Europeo di Oncologia |
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine (DDM) to improve health outcomes worldwide. We transform patient care with AI-driven technology that converts complex health data into actionable insights. Our cloud-native, IVDR-compliant SOPHiA DDM™ Platform enables accurate analysis, standardization, and interpretation of multimodal data in cancer and rare inherited disorders. Powered by patented AI algorithms, it breaks data silos, democratizes access to anonymized real-world insights, and connects a global network of 800+ healthcare institutions to accelerate research and precision care.
